MUC13 Mucin Augments Pancreatic Tumorigenesis

Subhash C. Chauhan1,3, Mara C. Ebeling1, Diane M. Maher1, Michael D. Koch4, Akira Watanabe5, Hiroyuki Aburatani5, Yuhlong Lio2, and Meena Jaggi1,3

Abstract

The high death rate of pancreatic cancer is attributed to the lack of reliable methods for early detection and underlying molecular mechanisms of its aggressive pathogenesis. Although MUC13, a newly identified transmembrane mucin, is known to be aberrantly expressed in ovarian and gastro-intestinal cancers, its role in pancreatic cancer is unknown. Herein, we investigated the expression profile and functions of MUC13 in pancreatic cancer progression. The expression profile of MUC13 in pancreatic cancer was investigated using a recently generated monoclonal antibody (clone PPZ0020) and pancreatic tissue microarrays. The expression of MUC13 was significantly (P < 0.005) higher in cancer samples compared with normal/nonneoplastic pancreatic tissues. For functional analyses, full-length MUC13 was expressed in MUC13 null pancreatic cancer cell lines, MiaPaca and Panc1. MUC13 overexpression caused a significant (P < 0.05) increase in cell motility, invasion, proliferation, and anchorage-dependent or -independent clonogenicity while decreasing cell–cell and cell-substratum adhesion. Exogenous MUC13 expression significantly (P < 0.05) enhanced pancreatic tumor growth and reduced animal survival in a xenograft mouse model. These tumorigenic characteristics correlated with the upregulation/phosphorylation of HER2, p21-activated kinase 1 (PAK1), extracellular signal-regulated kinase (ERK), Akt, and metastasin (S100A4), and the suppression of p53. Conversely, suppression of MUC13 in HPAFII pancreatic cancer cells by short hairpin RNA resulted in suppression of tumorigenic characteristics, repression of HER2, PAK1, ERK, and S100A4, and upregulation of p53. MUC13 suppression also significantly (P < 0.05) reduced tumor growth and increased animal survival. These results imply a role of MUC13 in pancreatic cancer and suggest its potential use as a diagnostic and therapeutic target.

Mol Cancer Ther; 11(1); 24–33. ©2011 AACR.

Introduction

In 2011, pancreatic cancer is estimated to be detected in more than 44,000 people and to account for more than 37,000 deaths in the United States (1). With an overall 5-year survival rate of only 5%, pancreatic cancer is the fourth most lethal cancer, accounting for 6% of all cancer-related deaths in both men and women (1). Together, the aggressive nature of pancreatic cancer combined with vague symptoms and lack of screening mechanisms create a difficult disease to treat. The serum tumor marker CA19-9 may be helpful in diagnosing pancreatic cancer, but it lacks sensitivity and specificity to effectively screen asymptomatic patients (2). Therefore, the identification of sensitive and specific markers is needed for early detection and subsequent treatment of pancreatic cancer.

Mucins (MUC) have been identified as potential tumor markers and attractive therapeutic targets (3, 4). Mucins form a physical barrier which provides protection for epithelial cells under normal physiologic conditions. However, mucins may be involved in cancer development when expression, localization, or glycosylation patterns change. Such changes can lead to increased cell growth, transformation, and decreased immune surveillance (3, 4). Mucin 13 (MUC13) is a recently identified transmembrane mucin which is normally expressed in the large intestine, trachea, kidney, small intestine, and gastric epithelium (5, 6). In recent studies, MUC13 has been shown to be aberrantly expressed in ovarian and gastro-intestinal cancers (7-9). MUC13 has a large 151-amino acid tandem repeat domain, 3 epidermal growth factor (EGF)-like domains, and a sea urchin sperm protein...
enterokinase arginine (SEA) domain within the extracellular component, followed by a short 23-amino acid transmembrane domain and a 69-amino acid cytoplasmic domain (5).

In this study, we show that MUC13 is overexpressed in pancreatic cancer and the exogenous expression of MUC13 augments tumorigenic features in pancreatic cancer cells, such as enhanced cell proliferation, cell motility, cell invasion, and in vivo tumor growth. Conversely, the suppression of MUC13 expression by short hairpin RNA (shRNA) in HPAFII cells shows the opposite effect. The expression of MUC13 correlates with the expression/activation of HER2, PAK1, ERK, Akt, and S100A4 and the decreased expression of p53. These results show, for the first time, the direct association of MUC13 with pancreatic cancer and its influence on pancreatic tumorigenesis.

Materials and Methods

Tissue specimens and immunohistochemistry

The tissue microarray slides (procured from AccuMax, ISU Abxis Co., Ltd and shown in Supplementary Data) and xenograft mouse tumor slides were stained using heat-induced antigen retrieval immunohistochemistry techniques with the Vector ABC kit (Vector Laboratories) with anti-MUC13 MAb (PPZ0020) and analyzed as previously described (9).

Cell culture, transfection procedure, and reagents

Human pancreatic cancer cells procured from American Type Cell Culture Collection were maintained at 37°C in recommended growth medium (MiaPaca: DMEM, HPAFII:DMEM/Ham’s F12) supplemented with 10% FBS and antibiotics (Hyclone Laboratories). To maintain authenticity of the cell lines, frozen stocks were prepared from initial stocks and every 6 months a new frozen stock was used for the experiments. The human MUC13 cloned in pcDNA3.1 or the empty vector was transfected into MiaPaca and Panc1 pancreatic cancer cells (Sigma) according to the manufacturer’s protocol. Stable transfected cells were then selected and maintained in media containing 500 μg/mL puromycin (Sigma). HPAFII cells were transduced with 5 different constructs of MUC13 specific shRNA lentiviral parti-

RNA isolation, reverse transcription PCR, and real-time PCR

Total RNA, reverse transcription, and PCR analysis was done as previously described (9). Briefly, RNA was collected via RNeasy Mini Kit (Qiagen) and reverse transcription was done with the Superscript II RNase H-Reverse Transcriptase System (Invitrogen). The result-

Immunofluorescence and confocal microscopy

Cells were grown at low density on chamber slides (Nalge Nunc Int.) for 24 hours and processed for immunofluorescence as described (9). Cells were incubated with anti-MUC13 MAb (clone PPZ2020) or HER2 polyclonal rabbit antibody (Dako) followed with species specific Alexa Fluor 488 or 568 secondary antibodies (Invitrogen) and mounted in FluoroCare Anti-Fade mounting medium (BioCare Medical). Laser confocal microscopy was done with an Olympus Fluoview FV1000 confocal microscope (Olympus Corporation).

Aggregation assay

For aggregation assays, cells (5,000) were pipetted in a volume of 25 μL of growth media onto the inner surface of the lid of a Petri dish as described earlier (9, 13). After overnight incubation at 37°C, the drops of cell suspension were pipetted to disrupt the loose aggregates and photographed with a phase-contrast microscope.

Cell migration/cell invasion assays

Cellular motility was determined by an agarose bead-based cell motility assay as described earlier (9). Briefly, cells were mixed into a low melting point agarose solution and drops of suspension were placed onto plates. At 24 and 48 hours the plates were photographed using a phase-contrast microscope. Cell motility was also analyzed with a Boyden's chamber assay as described earlier (9, 12). For cell invasion assays, BD Biocat Matrigel Invasion Chambers (BD Biosciences) were used as per manufacturer’s suggestions. After 48 hours incubation, the invading cells were stained and counted in 10 fields of view.

Cell proliferation assay

Cells (2 x 10^5) were seeded in 6-well plates in 2 mL of growth medium. At 24, 48, 72, and 96 hours, the cells were counted in triplicate using an automated cell counter (Z1 Coulter Particle Counter, Beckman Coulter). Doubling time (Td) of the cells was calculated from the growth rate during the exponential growth phase (0–96 hours) using

www.aacjrournals.org  Mol Cancer Ther; 11(1) January 2012 25
the formula, \( T_d = 0.693t / \ln(N_t/N_0) \), wherein \( t \) is time in days, \( N_t \) is cell number at time \( t \), and \( N_0 \) is cell number at initial time as described earlier (9, 12).

### Anchorage-dependent and -independent colony forming assays

For the anchorage-dependent colony forming assay, cells \((1 \times 10^5)\) were plated in 100 mm dishes, incubated for 10 days, washed with 1XPBS, fixed with 100% methanol and stained with hematoxylin. The colonies (>50 cells) were counted manually and plotted as described earlier (14). For the anchorage-independent colony forming assay, cells \((2 \times 10^5)\) were seeded in a 6-well plate in 1 mL of 0.3% complete media-agar over 2 mL of 0.6% complete media-agar. The cultures were maintained in a 37°C, 5% CO₂ incubator for 15 days. The colonies were counted in 6 photomicrographs from each well.

### Adhesion assays

100 μL of media containing \(1.0 \times 10^5\) cells were seeded (in triplicate) into wells of a 96-well plate coated with collagen, fibronectin, laminin, and basement membrane complex proteins (Calbiochem) and incubated for 1 hour at 37°C as described earlier (15). After incubation, the wells were gently washed twice with 1XPBS. The adherent cells were then incubated with 100 μL of calcein-AM for 1 hour at 37°C. The fluorescence of the samples was measured using a fluorescence plate reader at excitation wavelength of 485 nm and emission wavelength of 515 nm.

### In vivo tumor xenograft study

Six-week-old athymic Nu/nu nude mice were purchased from Charles River Laboratories International, Inc., and maintained in a pathogen-free environment. Each cell line was suspended in PBS and Matrigel (BD Bioscience) at a 1:1 ratio. Cell suspension \((5 \times 10^6\) cells in 200 μL) was injected subcutaneously into the right flank of each mouse. Tumor volume \((V)\) was estimated from the formula \( V = 0.52(l \times w \times h) \) as described previously (9). Mice were monitored until tumors reached 700 mm³ total volume, at which time mice were euthanized. Tumors were dissected and prepared for immunohistochemical analysis. All animal experiments were done using protocols approved by the Sanford Research/USD and The University of South Dakota Institutional Animal Care and Use Committee.

### Statistical analyses

Student t test for independent analysis was applied to evaluate differences in in vitro tumorigenic properties. Linear regression analysis was done to estimate tumor volume as a function of time. Kaplan–Meier analysis was used to estimate animal survival, and differences in survival were analyzed by log-rank analysis. Significant differences were determined using a paired t test. Values of \( P < 0.05 \) were considered significant. SAS software version 9.1.3 (SAS Institute Inc.) was used for all analyses.

### Results

#### MUC13 is overexpressed in human pancreatic cancers

Mucins have been reported to be overexpressed in pancreatic cancer (3, 16). However, the expression profile of MUC13 in pancreatic cancer has not been investigated. Therefore, we analyzed the expression pattern of MUC13 in normal/benign pancreas and pancreatic cancer tissue samples by immunohistochemistry using a MUC13 specific MAb (PPZ0020). MUC13 expression in normal, non-neoplastic pancreas samples was either undetectable or showed very faint staining. However, pancreatic cancer samples showed significantly \((P < 0.05)\) higher MUC13 expression (Supplementary Fig. S1). MUC13 was predominately localized on the apical membrane in the majority of cases with cytoplasmic localization in some cases (Supplementary Fig. S1). To determine the correlation of MUC13 expression with cancer type, cancer samples were grouped into histologic types (well differentiated, moderately differentiated, and poorly differentiated). MUC13 expression was significantly higher \((P < 0.05)\) in well and moderately differentiated types of pancreatic cancer compared with normal pancreatic tissue. A negative control antibody did not show any immunoreactivity.

#### MUC13 expression in pancreatic cancer cell lines

To select suitable cell lines for functional assays, we screened a panel of 5 pancreatic ductal adenocarcinoma cell lines (SW1990, Capan-1, HPAFII, MiaPaca and Panc1) for MUC13 expression by reverse-transcription PCR (RT-PCR) and confocal microscopy. Of these cell lines, HPAFII and Capan-1 showed high MUC13 expression, while MiaPaca, Panc-1, and SW1990 did not show detectable MUC13 expression (Supplementary Fig. S2A and B). On the basis of this data, MiaPaca, Panc1, and HPAFII cell lines were selected for overexpression and knockdown studies, respectively, to determine functional roles of MUC13 in pancreatic cancer.

#### Exogenous MUC13 expression enhances tumorigenesis in pancreatic cancer cells

To investigate MUC13 functions in pancreatic tumorigenesis, full-length MUC13 (MUC13F-pcDNA3.1) was overexpressed in MUC13-null cell lines, MiaPaca and Panc1, and several pools of clones were screened for MUC13 expression. Two pools, MP2 and MP4, were selected for further analysis due to their different expression levels of MUC13 (MP2: low; MP4: high) as determined by RT-PCR (Fig. 1A, left). These cells also showed homogenous expression of MUC13 in more than 90% of the cells as shown by confocal microscopy (Fig. 1A, right). Immunoblotting was not done for MUC13 expression.
MUC13 in Pancreatic Cancer

analysis due to the lack of anti-MUC13 antibodies appropriate for immunoblotting. High (MP4) and low (MP2) MUC13 expressing cells were selected to determine the effect of variable MUC13 expression in pancreatic cancer cells. The MiaPaca pcDNA3.1 (MPPC) vector-only transfected cells exhibited cell characteristics indistinguishable from the parental, MUC13 negative cell line (Fig. 1A, a and b). In a similar fashion, MUC13 expressing and MUC13 null stable cell lines were generated from Panc1 cells (Supplementary Fig. S4A).

Multiple in vitro assays were done to determine the effects of MUC13 expression on pancreatic cancer cell growth. High MUC13-expressing cells (MP4) showed significantly ($P < 0.05$) enhanced cell proliferation compared with vector control cells (Fig. 1B). Both MP2 and MP4 cells displayed lower cell doubling times of 17.6 and 16.5 hours, respectively, compared with 19.3 hours of MPPC control cells (Supplementary Fig. S3A). In anchor-age-dependent and independent colony formation assays, high MUC13-expressing cells (MP4) formed significantly ($P < 0.05$) higher number of colonies than MUC13-null cells (Fig. 1C and D). In addition, anchorage-dependent and independent colony formation assays were counted 15 days after plating in media-agar. The MiaPaca-derived colonies were counted 10 days after plating, D, anchorage-independent soft agar colony forming assays. The MiaPaca-derived colonies were counted 15 days after plating in media-agar. For B, C, and D, mean ± SE; $n = 3$; *, $P < 0.05$.

**MUC13 knockdown suppresses growth of pancreatic cancer cells**

To further confirm the role of MUC13 in pancreatic tumorigenesis, we knocked down MUC13 expression in HPAFII cells, which express high levels of MUC13, by using transduction with MUC13-specific shRNA lentiviral particles. A scrambled shRNA (sh-V-GFP) HPAFII stable cell line was also generated by transduction with GFP-shRNA lentiviral particles. Knockdown of MUC13 was confirmed by RT-PCR (Fig. 2A, left panel) and confocal microscopy (Fig. 2A, right panel). In vector control HPAFII sh-V-GFP cells, MUC13 expression was similar (Fig. 2A, b) compared with wild-type HPAFII cells (Fig. 2A, a). However, MUC13 expression in the knockdown cells was much lower than wild-type and vector cells, with shMUC13D having relatively greater knockdown of MUC13 compared with shMUC13A (Fig. 2A, c and d). Two pools of cells showing downregulation of MUC13 were selected to determine the effect of MUC13 expression in pancreatic cancer cells. Interestingly, MUC13 knockdown cells (shMUC13D) showed significant ($P < 0.05$) inhibition in cell proliferation compared with vector control cells (Fig. 2B) and displayed relatively higher cell doubling times (29.6 hours) compared with respective vector control HPAFII (26.3 hours) cells (Supplementary Fig. S3B). In addition, in anchorage-dependent and
-independent colony forming assays, MUC13 knockdown cells (shMUC13D) formed significantly (*P < 0.05) less colonies than vector control (sh-V-GFP; Fig. 2C and D).

**MUC13 expression correlates with motility, invasion, and adhesion of pancreatic cancer cells**

To elucidate the role of MUC13 in invasion and metastasis, we compared cell motility, invasion and adhesion in MUC13 overexpressing and MUC13 knockdown cells. In agarose-bead, Boyden’s chamber, and Matrigel invasion assays, MUC13-expressing clones showed higher cellular motility and invasion compared with vector control cells (Fig. 3A–C). Because an antiadhesive property would make cancer cells more motile and invasive, cells were assayed for their adhesion to extracellular matrix components and MUC13-expressing cells were less adhesive to fibronectin, basement membrane complex (BMC), and laminin than MUC13-nonexpressing cells (Fig. 3D). In addition, an aggregation assay showed that high MUC13-expressing cells (MP4) formed smaller and looser cell aggregates whereas the vector control formed smaller and looser cell aggregates (Fig. 4D).

**MUC13 expression influences tumorigenic cell signaling pathways**

Recently, in pancreatic cancer cells, the transmembrane mucin MUC4 was shown to interact with and stabilize HER2 at the cell membrane (17). As a transmembrane mucin with 3 EGF-like domains, MUC13 may also increase HER2 stability and signaling. To investigate this possibility, we examined HER2 expression and its phosphorylation status in MUC13-overexpressing and MUC13-knockdown cells. MUC13 overexpressing cells have increased HER2 and MUC13 knockdown cells have decreased HER2 expression (Fig. 5A and B). Accordingly, the tyrosine phosphorylation of HER2 (pY1248-HER2) increased in MUC13-overexpressing cells and decreased in MUC13-knockdown cells (Fig. 5A and B). We also examined downstream targets of HER2, such as Akt, PAK1, and ERK, which are parts of the phosphoinositide-3-kinase/Akt and mitogen-activated protein kinase pathways.
(MAPK) signal transduction pathways and play crucial roles in cancer progression (4, 18–24). As expected these targets also show altered expression/activation levels in MUC13 overexpressing and knockdown pancreatic cancer cells (Fig. 5A). Total and phosphorylated PAK1 and ERK were upregulated with MUC13-overexpression and downregulated with MUC13 knockdown (Fig. 5A). Even though total Akt levels remained the same, phosphorylated Akt was upregulated with MUC13-overexpression and was downregulated with MUC13 knockdown (Fig. 5A).

Given the importance of aberrant p53 in cancer development, we also examined the effect of MUC13 on p53 expression. Our data suggest downregulation of p53 at both RNA (data not shown) and protein levels in high MUC13-overexpressing cells compared with control cells (Fig. 5A). Conversely, p53 expression was upregulated upon knocking down MUC13 in HPAFII cells compared with control cells (Fig. 5A). These results imply a novel regulatory mechanism of p53 by MUC13 overexpression.

To investigate how MUC13 expression influences invasion of pancreatic cancer cells, we determined the expression of S100A4 in MUC13-overexpressing and MUC13-knockdown cells. A member of the S100 calcium-binding proteins, S100A4 is linked to cancer invasion and metastasis (25, 26). MUC13-overexpressing cells had higher RNA (data not shown) and protein levels of S100A4 compared with control cells (Fig. 5A). However, MUC13-knockdown cells (shMUC13D) showed lower RNA (data not shown) and protein levels of S100A4 compared with control cells (Fig. 5A).

MUC13 expression influences in vivo tumorigenicity

To determine the tumorigenic potential of MUC13 in vivo, we examined the tumor growth pattern of MUC13-expressing cells in a pancreatic cancer xenograft mouse model. MiaPaca cells expressing high MUC13 (MP4) formed significantly larger (P < 0.05) tumors and had reduced survival compared with MUC13 null (MPPC) cells (Fig. 6A). To confirm the association of MUC13 expression with tumor growth, we used MUC13 knockdown HPAFII cells for in vivo tumorigenesis and survival studies. Tumors from the MUC13 knockdown cells grew slower, were significantly smaller (P < 0.01), and mice had significantly improved survival compared with the mice injected with control cells (Fig. 6B). Analysis of xenograft
tumors by immunohistochemistry showed a change in HER2 and p53 expression in cells overexpressing MUC13 (MP4) or in cells with suppressed MUC13 expression (shMUC13D; Supplementary Fig. S5A and B). Similar to the in vitro analysis, in xenograft tumors, MUC13 overexpressing cells have increased HER2 and decreased p53, while MUC13 knockdown cells have decreased HER2 and increased p53.

Discussion

The high mortality rate from pancreatic cancer is primarily attributed to the inability to detect pancreatic cancer at an early stage, limited knowledge regarding the etiology of the aggressiveness of the disease, and lack of an effective treatment modality (2). These facts accentuate the need to identify novel molecular markers for early diagnosis of pancreatic cancer and to reveal underlying molecular mechanisms of the aggressiveness of the disease. In this study, for the first time, we have investigated the expression profile of a newly identified transmembrane mucin, MUC13, and its functional role in pancreatic cancer progression. Our data show that MUC13 is highly overexpressed in pancreatic tumors compared with undetectable or faint expression in normal pancreas. MUC13 expression correlated with the differentiation status of the tumor and was highest in well-differentiated tumor samples and lowest in poorly differentiated tumor samples (Supplementary Fig. S1). Our findings suggest that MUC13 is a pancreatic tumor-associated molecule and may be useful for pancreatic cancer diagnosis. Given that biochemical analysis suggests that MUC13 is cleaved within the SEA domain (5, 6), our extracellular luminal staining results suggest that MUC13 may be shed from pancreatic cancer cells and released into the blood. In addition, we have seen a progressive increase in expression and aberrant localization of MUC13 in pancreatic intraepithelial (PanIN) lesions (data not shown). For these reasons, there is a strong possibility that a MUC13-based serum immunoassay can be developed as a screening method for pancreatic cancer. Moreover, the intense membrane staining (Supplementary Fig. S1) also indicates that MUC13 may be an excellent target for antibody-guided therapy of pancreatic cancer.
To elucidate the functional roles and signaling pathways influenced by MUC13 in pancreatic cancer, we exogenously expressed MUC13 in MiaPaca and Panc1 cells which resulted in increased cell proliferation and colony forming efficiency of these cells. Conversely, MUC13 knockdown in HPAFII caused a decrease in cell proliferation and colony forming efficiency. The cellular response to altered MUC13 expression was more pronounced in cells showing higher expression or greater knockdown of MUC13, indicating a variable effect depending upon the level of MUC13 expression. In our xenograft mouse studies, MUC13 expression significantly augmented pancreatic tumor growth and reduced mice survival (Fig. 6A). In contrast, suppression of MUC13 expression markedly reduced tumor growth and improved animal survival (Fig. 6B). Because of its 3 EGF domains, MUC13 may influence expression, stabilization, recycling, and activation of EGF receptors, such as HER2, which in turn may modulate the EGF receptor cascade and its downstream signaling. Our data show that MUC13 modulates HER2 expression and its phosphorylation at tyrosine 1248, which in turn, induces oncogenic downstream targets of HER2, Akt and ERK (Fig. 5). Activation of PI3K/Akt and MAPK signaling pathways by HER2 have been implicated in the regulation of tumorigenesis (24, 27, 28).

Mutations in p53 have been well documented in a variety of cancers, including pancreatic cancer, and such mutations often create an oncogenic environment favoring tumorigenesis. Currently, our data suggest that MUC13 expression decreases the expression of p53. At this time, it is unknown if MUC13 regulates the expression of wild-type and/or mutant p53 as both forms can be detected by the immunologic methods (IHC and WB) used in our study (the cell lines used have mutated p53; refs. 29, 30). It has been reported that suppression of mutant p53 can lead to a decrease in MiaPaca cell proliferation through enhanced Id2 expression (31). Our results may seem contradictory to the previous study as MUC13 overexpression was associated with decreased p53 and increased cell proliferation. However, our data also show that MUC13 expression activates growth signaling pathways (HER2, PAK1, ERK, and Akt). Therefore, upon MUC13 overexpression, any inhibition in cell growth due to the reduction of mutant p53 would be countered by increased signaling through potent growth signaling pathways. The link between MUC13 and p53 expression may be mediated by intermediates (e.g., through activation of HER2) or could be mediated directly by the cytoplasmic tail of MUC13 (MUC13-CT). Another member of the transmembrane mucin family, MUC1, has been shown to inhibit transcription of p53 through binding of the MUC1 cytoplasmic tail (MUC1-CT) with Kruppel-like factor 4 (KLF4) which enhances binding to PE21 (a p53 repressor; ref. 32). A similar interaction is possible with the cytoplasmic tail of MUC13 although future experiments are needed to resolve this issue.

MUC13-overexpression in MiaPaca cells increased motility and invasion, while suppression of MUC13 decreased cellular motility and invasion in HPAFII cells. Overexpression of PAK1 enhances migration of breast, hepatocellular, and colorectal cancer cells and regulates the actin cytoskeleton during cell motility (33, 34). In contrast, knockdown of MUC13 increases PAK1 activity and leads to the promotion of cell invasion (33, 34).
addition, S100A4 is associated with metastasis and invasion (25, 26). Cancers expressing high levels of S100A4 have a worse prognosis compared with S100A4 negative cancers (35). Interestingly, PAK1 and S100A4 increased with MUC13 expression and decreased with MUC13 suppression (Fig. 5). In this study, we provide evidence to suggest that MUC13 plays a role in the invasiveness of human pancreatic cancer through the expression and/or activation of PAK1 and S100A4.

MUC13 has a heavily glycosylated extracellular tandem repeat domain (5) which may contribute to the antiadhesiveness of cells (16). Herein, we provide functional evidence that the overexpression of MUC13 in MiaPaca cells resulted in reduced cell–cell and cell-matrix adhesion. On the contrary, MUC13 knockdown in HPAFII cells resulted in increased cell–cell and cell-matrix adhesion (Figs. 3 and 4). Reduced cell–cell adhesion due to altered expression or function of cadherins may allow cancer cells to disseminate from sites of localized cancer and invade surrounding tissues (36, 37). Therefore, MUC13 induced changes in cell adhesion characteristics may potentiate invasion, metastasis, and aggressiveness of pancreatic cancer.

In conclusion, our data provide novel evidence for the aberrant expression of MUC13 in pancreatic tumors and indicates the role of MUC13 in pancreatic tumorigenesis and progression. We propose that MUC13 is overexpressed in pancreatic cancer and induces cellular motility, proliferation, and invasion through modulation of HER2, PAK1, Akt, S100A4, and p53 expression/activation. Further investigations are needed to understand the comprehensive molecular mechanisms of MUC13 and HER2 interplay in pancreatic cancer. This work is the first demonstration of the direct association of MUC13 with pancreatic cancer.
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Cathy Christopherson for editorial assistance. The authors also thank Dr. Keith Miskimins for his constructive suggestions. The authors also thank Sanford Research/USD Core facilities, which are supported by P20 RR17662 and P20RR024219 COBRE grants.

References

Molecular Cancer Therapeutics

MUC13 Mucin Augments Pancreatic Tumorigenesis

Subhash C. Chauhan, Mara C. Ebeling, Diane M. Maher, et al.

*Mol Cancer Ther* 2012;11:24-33. Published OnlineFirst October 25, 2011.

**Updated version**
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-11-0598

**Supplementary Material**
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2011/10/14/1535-7163.MCT-11-0598.DC1

**Cited articles**
This article cites 37 articles, 15 of which you can access for free at:
http://mct.aacrjournals.org/content/11/1/24.full#ref-list-1

**Citing articles**
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/11/1/24.full#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.